Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Clinical and Experimental Medicine|August 9, 2023
Characteristics and classification of first primary cancer patients with second primary cancer: a population-based cohort studyZhaohui Ruan, Yuetong Zhang, Zhaozhi Li, et al.Ecotoxicology and Environmental Safety|May 14, 2024
Associations of phthalates with accelerated aging and the mitigating role of physical activityTingting Qian, Jie Zhang, Jintao Liu, et al.Journal of Colloid and Interface Science|February 7, 2021
Porous cauliflower-like molybdenum disulfide/cadmium sulfide hybrid micro/nano structure: Enhanced visible light absorption ability and photocatalytic activityXing Liu, Zhaohui Ruan, Lu Zhang, et al.Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIsRenzhi Zhang, Huan Yan, Fang Tian, et al.Chinese Medical Journal Pulmonary and Critical Care Medicine|July 3, 2026
Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challengesFang Tian, Songkai Wang, Zhe Huang, et al.Cancer|December 8, 2025
Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancerZhe Huang, Zhaohui Ruan, Shidong Xu, et al.Journal of Oncology|October 16, 2020
Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South ChinaQianyu Wang, Guifang Guo, Zhaohui Ruan, et al.Journal of Translational Medicine|December 12, 2025
Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancerJiacheng Dai, Huan Yan, Yangqian Chen, et al.Clinical Lung Cancer|August 9, 2025
Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase InhibitorsYuanze Sun, Dan Yang, Zhe Huang, et al.Cell Reports. Medicine|June 30, 2026
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trialHuan Yan, Wenjuan Jiang, Yi Xiong, et al.Pageof 4